MAIA Biotechnology Hits Enrollment Milestones in Lung Cancer Trials
MAIA Biotechnology has completed enrollment in one trial phase and reached 65% of its 2026 target in a pivotal Phase 3 lung cancer study.
MAIA Biotechnology has reported significant patient enrollment progress across two active clinical trials targeting non-small cell lung cancer, a disease that represents one of the most common and lethal forms of the illness worldwide.
The company announced that enrollment has been fully completed in Part C of its THIO-101 Phase 2 study, a milestone that moves the trial closer to generating the data needed to assess the therapy's early-stage efficacy and safety profile.
Read more Foundation Group Merges Two Units Into Nonprofit Accounting Division →
Separately, MAIA disclosed that its pivotal THIO-104 Phase 3 study has now reached 65% of its enrollment target set for 2026. Achieving that benchmark suggests the trial is tracking ahead of or on pace with the company's internal planning timeline, a positive signal for investors and clinical stakeholders monitoring the program's progress.
The THIO-104 trial carries particular weight given its pivotal designation, meaning successful results could form the basis of a regulatory submission. Non-small cell lung cancer accounts for the large majority of lung cancer diagnoses, making effective new treatments a high clinical priority across oncology research.
MAIA has not disclosed interim efficacy data from either study at this stage, and completion of enrollment does not guarantee favorable outcomes. The company's continued progress on both fronts, however, signals operational momentum in a competitive and scientifically demanding therapeutic area. Continue reading at GlobeNewswire - Industry News on Financial Services.
